Quantitative susceptibility mapping as an imaging biomarker for Alzheimer’s disease: The expectations and limitations Yuto Uchida, Hirohito Kan, Keita Sakurai, Kenichi Oishi and Noriyuki Matsukawa Frontiers In Neuroscience, 5 august 2022 Alzheimer’s disease (AD) is the most common type of … Read More
How and why should software testing be implemented? Davy becomes ISTQB expert In December 2022, Davy obtained the ISTQB Advanced Test Analyst certification after the first level in June 2022, allowing him to master level for the implementation and good … Read More
Ventio joins Medicen for the development of innovative health technologies. Medicen is 120 companies in the Innovation-Diagnostics cluster, a “Core TEAM Imaging” working group, and a recent “Brain-STORM” call for interest for transversal research projects in the field of neurodegenerative … Read More
Ahead : We are sponsor of the 2023 congress of the French Society of Magnetic Resonance and Medical Biology (Société Française de Résonance Magnétique et de Biologie Médicale, SFRMBM). We will be present during the 3 days of this event. … Read More
SNITEM
Ventio receives the Medical Imaging Innovation Award (JFR, Paris, 2022) The 70th edition of the Journées Francophones de Radiologie Diagnostique et Interventionnelle (JFR) was held from 7 to 10 October in Paris. To support innovative startups in the field of … Read More
QMR Joint Workshop on MR phase, magnetic susceptibility and electrical properties mapping Lucca (Italy) is, for few days, the “centre of the world” for magnetic susceptibility and QSM medical imaging technology. Ventio, exclusive distributor of the technology in Europe in … Read More
Ventio participates to the follow-up of Alzheimer’s disease patients by offering a patented, innovative and quantitative technology for the follow-up of neuronal lesions by cerebral imaging: the Quantitative Susceptibility Mapping (QSM) technology. Ventio, with the QSM technology, is alongside … Read More
